Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Finished Goods (2016 - 2025)

Avanos Medical's Finished Goods history spans 11 years, with the latest figure at $87.9 million for Q3 2024.

  • For Q3 2024, Finished Goods rose 0.8% year-over-year to $87.9 million; the TTM value through Sep 2024 reached $87.9 million, up 0.8%, while the annual FY2023 figure was $88.5 million, 26.79% up from the prior year.
  • Finished Goods for Q3 2024 was $87.9 million at Avanos Medical, up from $86.2 million in the prior quarter.
  • Across five years, Finished Goods topped out at $103.4 million in Q1 2023 and bottomed at $69.8 million in Q4 2022.
  • The 5-year median for Finished Goods is $86.2 million (2024), against an average of $84.6 million.
  • The largest annual shift saw Finished Goods fell 20.8% in 2021 before it increased 29.57% in 2023.
  • A 5-year view of Finished Goods shows it stood at $90.4 million in 2020, then dropped by 20.8% to $71.6 million in 2021, then fell by 2.51% to $69.8 million in 2022, then rose by 26.79% to $88.5 million in 2023, then decreased by 0.68% to $87.9 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Finished Goods are $87.9 million (Q3 2024), $86.2 million (Q2 2024), and $84.0 million (Q1 2024).